Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details)

v3.22.1
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Warrant liability [1] $ 8 $ 71
Notes payable 7,835 7,942
Fair value of liabilities  9,676 9,884
Fair Value Measured at Net Asset Value Per Share [Member]    
Warrant liability [1] 8 71
Notes payable 7,835 7,942
Fair value of liabilities  9,676 9,884
Fair Value, Inputs, Level 1 [Member]    
Warrant liability [1]
Notes payable
Fair value of liabilities 
Fair Value, Inputs, Level 2 [Member]    
Warrant liability [1]
Notes payable
Fair value of liabilities 
Fair Value, Inputs, Level 3 [Member]    
Warrant liability [1] 8 71
Notes payable 7,835 7,942
Fair value of liabilities  9,676 9,884
Asuragen [Member]    
Contingent consideration [1] 1,833 1,871
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member]    
Contingent consideration [1] 1,833 1,871
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member]    
Contingent consideration [1]
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member]    
Contingent consideration [1]
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member]    
Contingent consideration [1] $ 1,833 $ 1,871
[1] See Note 9, Accrued Expenses and Long-Term Liabilities